Cancer Genetics spikes on Aegis Capital initiation

|About: Cancer Genetics, Inc. (CGIX)|By:, SA News Editor

Cancer Genetics (CGIX +15.4%) shares spike after Aegis Capital initiates the molecular diagnostics company at Buy with an 18-month PT of $25 (potential upside of 80%).

Analyst Raghuram Selvaraju is bullish on Cancer Genetics' "broad pipeline of tests ... both commercialized and under development, and with its ability to generate high-margin revenue from partnerships with biopharmaceutical firms that are seeking to develop theranostic solutions for patients."

He also thinks the company's CLIA-accredited facility, which can perform a variety of advanced screens, 'provides the sort of flexibility not seen in other molecular diagnostics firms."